Common diabetes drug tested to protect uterus in breast cancer treatment
NCT ID NCT07145827
Summary
This study tested whether metformin, a common diabetes medication, could reduce thickening of the uterine lining in postmenopausal women with estrogen-positive breast cancer who take tamoxifen. Researchers compared 60 women taking tamoxifen plus metformin against those taking tamoxifen plus a placebo over 12 months, measuring uterine lining thickness with ultrasounds. The goal was to see if metformin could help control this side effect of tamoxifen treatment while monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baghdad Medical City / Department of Oncology
Baghdad, Baghdad Governorate, 10045, Iraq
Conditions
Explore the condition pages connected to this study.